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Abstract
The STE20/SPS1-related proline/alanine-rich kinase (SPAK) controls blood pressure (BP) by phosphorylating and stimulating the
Na-Cl (NCC) andNa-K-2Cl (NKCC2) co-transporters, which regulate salt reabsorption in the kidney. SPAK possesses a conserved
carboxy-terminal (CCT) domain, which recognises RFXV/I motifs present in its upstream activator [isoforms of the With-No-
lysine (K) kinases (WNKs)] aswell as its substrates (NCC andNKCC2). To deﬁne the physiological importance of theCCTdomain,
we generated knock-inmice inwhich the critical CCT domain Leu502 residue required for high afﬁnity recognition of the RFXI/V
motif was mutated to Alanine. The SPAK CCT domain defective knock-in animals are viable, and the Leu502Ala mutation
abolished co-immunoprecipitation of SPAK with WNK1, NCC and NKCC2. The CCT domain defective animals displayed
markedly reduced SPAK activity and phosphorylation of NCC and NKCC2 co-transporters at the residues phosphorylated
by SPAK. This was also accompanied by a reduction in the expression of NCC and NKCC2 protein without changes in mRNA
levels. The SPAK CCT domain knock-in mice showed typical features of Gitelman Syndrome with mild hypokalaemia,
hypomagnesaemia, hypocalciuria and displayed salt wasting on switching to a low-Na diet. These observations establish that
theCCTdomainplays a crucial role in controlling SPAKactivityandBP. Our results indicate that CCTdomain inhibitorswould be
effective at reducing BP by lowering phosphorylation as well as expression of NCC and NKCC2.
Introduction
SPAK (SPS1-related proline/alanine-rich kinase) andOSR1 (oxida-
tive stress-responsive kinase 1) are closely related protein
kinases, which play key roles in regulating cellular ion homeosta-
sis and blood pressure (BP) (1,2). SPAK and OSR1 are activated fol-
lowing the phosphorylation of their T-loop residue (SPAK Thr233
and OSR1 Thr185) by one of the four isoforms of the WNK [with
no lysine (K) kinase] protein kinase (3,4). The activity of SPAK
and OSR1 is further enhanced following interaction with the
scaffolding protein termed MO25 (5). The best-characterised
SPAK/OSR1 substrates comprise the SLC12A (solute carrier family
12) family of electroneutral CCCs (cation–Cl co-transporters)
(6–11). These transporters regulate intracellular chloride concen-
tration critical in controlling BP and cell volume homoeostasis
(12,13). SPAK/OSR1 protein kinases drive chloride inﬂux by phos-
phorylation and activating sodium-driven CCC members. These
include the NCC (Na–Cl co-transporter) in the distal convoluted
tubule of the kidney (10), the NKCC2 (Na–K–2Cl co-transporter
2) in the thick ascending limb (TAL) of the kidney (9) and the ubi-
quitously expressed NKCC1 (6–8). SPAK/OSR1 also phosphorylate
and inhibit potassium-driven CCCs that drive chloride efﬂux (11),
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which comprise four different K–Cl− co-transporters (KCC1–
KCC4) (13,14). This reciprocal regulation of Na+- and K+-driven
CCCs by SPAKandOSR1 ensures that cellular Cl− inﬂux and efﬂux
is tightly co-ordinated (13,14).
The importance of theWNKsignalling pathway is exempliﬁed
by its evolutionary conservation fromworms to humans and that
several Mendelian hypertension disorders in humans are caused
by mutations in WNK pathway components (15,16). These in-
clude various mutations that lead to increased expression of
theWNK1 andWNK4 genes causing PHAII [PseudoHypoAldoster-
onism type II, OMIM (17–23)]. Conversely, loss-of-function muta-
tions in NCC andNKCC2 cause familial forms of hypotension and
hypokalaemia termed Gitelman (OMIM #263800) and Bartter type
1 syndrome (OMIM #601678), respectively (24). A mutation that
ablates the key activating WNK-regulated SPAK/OSR1 phosphor-
ylation site on NCC [T60M (10)] also causes Gitelman’s syndrome
(25,26). Moreover, SPAK-knockout mice (27–29) or knock-in mice
expressing a form of SPAK that cannot be activated by WNK ki-
nase isoforms (30) exhibit low BP and are resistant to hyperten-
sion when crossed with animals bearing a PHAII-causing
knock-in mutation that enhances WNK4 expression (31). Gen-
ome-wide association studies have also identiﬁed intronic SNPs
within the SPAK gene (STK39) that correlate with increased BP in
humans (32). Two commonly used drugs in medicine to lower
high BP also target SPAK sodium-driven CCC substrates, namely
thiazide diuretics (such as bendroﬂumethiazide) that inhibit NCC
and the loop diuretics (such as furosemide) that inhibits NKCC2
(33,34).
These data suggest that chemical agents that inhibit SPAK
would have the potential to treat hypertension, but without
the off-target effects of agents like thiazide diuretics (16,35).
One approachwould be to elaborate smallmolecule compounds
that directly inhibit SPAK/OSR1 protein kinase activity (36).
However, to our knowledge, no highly selective and potent ki-
nase inhibitors of SPAK and OSR1 have been reported. There is
also concern whether sufﬁciently selective SPAK/OSR1 kinase
inhibitors could be synthesized for themanagement of a chron-
ic largely asymptomatic condition, without them inhibiting
other protein kinases or ATP-binding enzymes and causing in-
tolerable off-target effects. An alternative strategy to suppress
SPAK/OSR1 function would be to target the docking domain
within the non-catalytic C-terminal region of SPAK/OSR1 called
the CCT (conserved C-Terminal) domain. In vitro and overex-
pression studies indicate that the CCT domain binds to con-
served RFXV/I motifs present on WNK isoforms and that these
interactions facilitate phosphorylation and activation of SPAK/
OSR1 (37,38). Furthermore, the sodium-driven CCC members
also possess conserved RFXI/V motifs at their N-terminus
which experimental data indicate are critical for enabling
SPAK/OSR1 to interact with, phosphorylate and stimulate activ-
ity of these transporters (9,10,38,39).
In this study,we sought to deﬁne the role that theCCTdomain
plays in vivo by generating and characterising SPAK knock-in
mice in which function of the CCT domain has been ablated by
a mutation of the critical Leu502 residue required for high-afﬁn-
ity binding of the RFXI/V motif. Our data demonstrate that the
CCT domain of SPAK does indeed play an essential role in regu-
lating the activation and function of SPAK. Our ﬁndings establish
that SPAK CCT domain knock-in mice display markedly reduced
phosphorylation and expression of NCC andNKCC2 in the kidney
resulting in lower BP. Our data provide genetic validation that
targeting the CCT domain would be therapeutically effective in
reducing BP, by lowering phosphorylation as well as expression
of NCC and NKCC2 in the kidney.
Results
Characterisation of a mutation that inhibits the CCT
domain of SPAK
Previous crystallographic analysis of the human OSR1 CCT do-
main complexed to an RFXI motif-containing peptide derived
from WNK4 (40) revealed that the highly conserved Leu473 CCT
residue lying at the base of a deep hydrophobic pocket formed
critical hydrophobic contacts with the Phe residue of the RFXI
motif (Fig. 1A). Consistent with this, mutation of Leu473 to Ala re-
duced binding of OSR1 to RFXI WNK4 peptide over 100-fold (40).
Mutation of the equivalent residue (Leu502) in mouse SPAK
also prevented full-length mouse SPAK co-immunoprecipitating
with endogenously expressed WNK1 and NKCC1 in HEK293 cells
(Fig. 1B). Moreover, in vitro ﬂuorescence polarisation studies con-
ﬁrmed thatmutation of this Leu residue in the SPAK CCT domain
reduced binding to an RFXV-motif-possessing peptide derived
from WNK4 by ∼100-fold (Fig. 1C).
Characterization of CCT domain-deﬁcient
SPAKL502A/L502A mice
We exploited these observations to explore the impact that mu-
tation of the CCT domain Leu502 residue had, by generating
knock-in mice on an inbred C57BL/6J background, in which the
Leu502 CCT domain residuewas changed to Ala (Fig. 2A). Homo-
zygous SPAKL502A/L502A mice were born at the expected Mendel-
ian frequency (Supplementary Material, Table S1), were of
normal size and appearance and did not display any overt
phenotype, at least up to 1 year of age (the oldest animals we
have analysed).
Immunoblot analysis of tissues (kidney, brain, heart and testis)
derived from littermate wild-type and SPAKL502A/L502A homozy-
gous animals of 2 months of age employing a novel mouse SPAK
antibody that we generated that does not recognise mouse OSR1
(Supplementary Material, Fig. S1) revealed that the L502A muta-
tion did not inﬂuence expression of SPAK in these tissues. We ob-
served that all tissues analysed derived from SPAKL502A/L502A mice
displayed a signiﬁcant reduction of the phosphorylation of SPAK
at a key WNK phosphorylation site [Ser373 (3)], compared with
wild-type mice (Fig. 2B). This is consistent with the L502A muta-
tion suppressing the ability of WNK isoforms to phosphorylate
SPAK. Furthermore, the SPAKL502A/L502A knock-in animals dis-
played markedly reduced phosphorylation of NKCC1, in agree-
ment with the CCT domain being required for SPAK to bind to
and phosphorylate NKCC1 (Fig. 2B).
To obtain further evidence that the L502Amutation impacted
on the ability of SPAK to bind WNK1 and NKCC1, we immuno-
precipitated SPAK from kidney, brain and testis, derived from
littermate wild-type and SPAKL502A/L502A homozygous animals
of 2 months of age and tested how CCT domain mutation
effected in association with WNK1 and NKCC1. This revealed
that in the SPAKL502A/L502A knock-in animals, co-immunopreci-
pitation of WNK1 and NKCC1 with SPAK was markedly reduced
in all tissues analysed (Fig. 2C). In the kidney, we also observed
that mutation of the CCT domain inhibited co-immunoprecipi-
tation of NCC and NKCC2 with SPAK (Fig. 2C). Further immuno-
blot analysis of SPAK immunoprecipitates conﬁrmed that the
L502A mutation inhibited phosphorylation of SPAK at the two
key residues that WNK isoforms phosphorylate [Thr243 and
Ser373 (3)] (Fig. 2C). SPAK as well as OSR1 immunoprecipitates
from tissues (kidney, brain and testis) were also subjected to a
protein kinase assay activity assay employing the previously
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described CATCHtide peptide that encompasses the NKCC1
phosphorylation sites (37). This revealed that SPAK immunopre-
cipitated from all tissues derived from SPAKL502A/L502A knock-in
mice displayed signiﬁcantly reduced activity compared with
wild-type animals (Fig. 2D). As expected, the activity of OSR1
was not affected in SPAKL502A/L502A knock-in mice (Fig. 2D).
SPAKL502A/L502A mice display reduced phosphorylation of
NCC and NKCC2 in kidney
We next compared the relative levels of phosphorylation of NCC
in total kidney extracts derived from male and female 2-month-
old wild-type and SPAKL502A/L502A knock-in littermate animals
(Fig. 3A–D). We monitored phosphorylation of NCC employing
different previously characterised phosphospeciﬁc antibodies
recognising major SPAK NCC phosphorylation sites (Thr46,
Thr50, Thr55, Thr60 and Ser91) (10). This revealed that in both
male and femalemice, the phosphorylation of NCC at all residues
analysed was drastically reduced in kidney derived from
SPAKL502A/L502A knock-in mice compared with wild type
(Fig. 3B). Similar to what was previously observed in SPAK kinase
inactive (SPAKT243A/T243A) knock-in mice (30) as well as SPAK
knockout mice (27–29), we also observed ∼2-fold reduction in
total levels of NCC protein in kidney extracts of SPAKL502A/L502A
knock-in mice compared with wild type (Fig. 3B). In contrast,
kidney mRNA levels of NCC were similar in wild-type and of
SPAKL502A/L502A knock-in mice (Supplementary Material, Fig. S2).
We next monitored NKCC2 expression and similarly to NCC
observed that levels were reduced ∼2-fold in the kidney of
SPAKL502A/L502A knock-in male and female mice compared with
wild-type animals (Fig. 3C). We immunoprecipitated NKCC2
and analysed its phosphorylation at three residues that
SPAK phosphorylates [Ser91, Thr100 and Ser130 (9)] and
found that phosphorylation of each of these residues was sub-
stantially reduced in both male and female kidney derived from
SPAKL502A/L502A knock-in animals (Fig. 3C). KidneymRNA levels of
NKCC2 were similar in wild type and of SPAKL502A/L502A knock-in
mice (Supplementary Material, Fig S2).
We also analysed NKCC1 and found that the levels of this co-
transporterwere unaffected in kidneyextracts derived fromwild-
type and SPAKL502A/L502A knock-inmale and femalemice (Fig. 3D).
We immunoprecipitated NKCC1 and analysed its phosphoryl-
ation at four sites that SPAK phosphorylates [Thr203, Thr207,
Thr212 and Thr217 (3,5)] and found that phosphorylation of
these sites was markedly diminished in both male and female
kidney extracts derived from SPAKL502A/L502A knock-in animals
compared with wild type. Kidney mRNA levels of NKCC1 were
similar in wild-type and of SPAKL502A/L502A knock-in mice
(Supplementary Material, Fig. S2).
SPAKL502A/L502A mice show a marked reduction in
immunostaining for phosphorylated NCC and NKCC2
without remodelling of kidney tubules
Confocal imaging of kidney sections from the SPAKL502A/L502A
mice conﬁrmed the modest reduction in total NCC and NKCC2
in the tubules of the distal convoluted (DCT) and TAL tubules
compared with wild-type mice, with no obvious changes in
the morphology and numbers of tubules or the intracellular pro-
tein distribution between genotypes (Fig. 4). In striking contrast,
staining for the phosphorylated forms of NCC and NKCC2 in the
same tubules was almost completely lost in the SPAKL502A/L502A
mice in keeping with the immunoblots from whole kidney
lysates (Fig. 3). Additionally no changes were observed in the
intracellular localisation ofWNK4 in theDCTor TAL (Supplemen-
tary Material, Fig. S3).
Figure 1. Evidence that SPAK associates with WNK1 and interaction is disrupted
by SPAK CCT mutation. (A) Molecular interaction of the RFXV peptide with the
conserved carboxy-terminal domain of OSR1 based on PDB 2V3S: CCT domain
of OSR1 (residues 434–527) coloured in grey (β-strands and α-helices) bound to
the GRFQVT WNK4-derived peptide coloured in blue. (B) HEK293 cells were
transfected with constructs encoding a Flag empty vector or the indicated wild-
type or mutant construct of N-terminal FLAG epitope-tagged full-length mouse
SPAK. Thirty-six hours post-transfection, cells were lysed. Total cell extracts
were subjected to immunoprecipitation (IP) with the indicated SPAK antibody,
and immunoprecipitates were subjected to immunoblot (IB) analysis employing
WNK1, SPAK and NKCC1 antibodies. Similar results were obtained in three
separate experiments. (C) Analysis of SPAK–WNK interaction by ﬂuorescence
polarization. Puriﬁed human SPAK 452–547(end) and human SPAK 452–547 with
L491A (equivalent to L502 in mouse) were diluted appropriately and mixed at a
1:1 volume ratio with 20 n Lumino-Green-labelled WNK peptide to the
concentration stated in the figure, with the peptide concentration consistent at
10 n, and ﬂuorescent polarization measurements were made. Binding curves,
assuming one-site-speciﬁc binding, were then generated with Prism6 using
milli-polarization (mP) units.
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Figure 2. Targeting strategy used to generate SPAK knock-in mutations. (A-1) Diagram depicting the knock-in construct, the endogenous SPAK allele containing exons
15–16 and the targeted allele with the puromycin cassette removed by Flp recombinase. The black/grey rectangles represent exons, and the grey triangles represent
FRT sites. Black lines with arrowheads are used to indicate the positions of the probes used for Southern analysis. The knock-in allele containing the Leu502Ala
mutation in exon 16 is illustrated as a grey rectangle. The knock-in allele can be detected by genotyping using PCR primers P1 and P2, which are represented by short
black lines with arrowheads. (A-2) Genomic DNA puriﬁed from the targeted ES cells from the indicated genotypes was digested with either the SexAI or Kpnl and Aﬂll
and subjected to Southern analysis with the corresponding DNA probes. In the case of the 5′ probe, the wild-type allele generates a 13.5-kb fragment whereas the
knock-in allele produces a 11.2-kb fragment. Similarly, the 3′ probe detects a fragment of 11.9 kb from the wild-type allele and 10.2 kb from the targeted knock-in
allele. (A-3) Genomic DNA was PCR ampliﬁed with primers P1 and P2. The wild-type allele generates a 344-bp product whereas the knock-in allele generates a 419-bp
product. The larger knock-in allele product is due to the presence of the 75-bp FRT site and ﬂanking region, which remains in an intronic region following Flp-
mediated excision of the puromycin resistance (PuroR) selection cassette, whereas the Thymidine kinase as a negative selection. (A-4) Genomic DNA puriﬁed from
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SPAKL502A/L502A mice display reduced BP and
augmentation index
To study the cardiovascular phenotype of these mice, we mea-
sured the arterial BP in the SPAKL502A/L502A knock-in animals by
carotid artery cannulation under general anaesthesia, which
showed that their systolic, diastolic and mean arterial BPs were
∼20 mmHg lower than wild-type littermates (Fig. 5A). The lower
BP of the SPAKL502A/L502A knock-in animals was also reﬂected in
a signiﬁcantly lower left ventricular mass in these animals (Sup-
plementary Material, Fig. S4).
Further analysis of the BP traces from the mice also showed
that the shape of the arterial pressurewavewas signiﬁcantly dif-
ferent (Fig. 5B). The SPAKL502A/L502A knock-in animals have a
lower diastolic pressure time decay constant (τbourgeois), an
index of vascular resistance (41), suggesting decreased vascular
tone compared with wild-type littermates (Fig. 5B). Speciﬁcally,
the SPAKL502A/L502A knock-in animals had lower augmentation
of the peak systolic pressure (AIx) with no change in pulse pres-
sure consistent with a reduction in arterial stiffness (42) (Fig. 5B).
SPAKL502A/L502A mice show a Gitelman syndrome pattern
of plasma and urinary electrolytes and are salt wasting
Analysis of the plasma electrolytes showed that the SPAKL502A/L502A
mice had a typical Gitelman pattern of plasma electrolytes with
hypokalaemia and mild hypomagnesaemia compared with the
wild-type animals (Fig. 6A). This is consistent with reduced
WNK pathway signalling caused by the inactivation of the SPAK
CCT domain. The urinary electrolytes also showed a Gitelman-
like pattern of electrolytes with marked hypocalciuria compared
with the wild-type mice (Fig. 6B). The salt wasting expected of a
Gitelman-like phenotype was also conﬁrmed by salt restricting
the SPAKL502A/L502A knock-in animals by switching to a 100-fold
lower Na diet (Fig. 6C).
Discussion
Our results deﬁne the importance that the CCT-docking domain
plays in regulating the ability of WNK isoforms to control the ac-
tivation as well as function of SPAK in regulating NCC/NKCC2 ion
co-transporters and hence BP. Most importantly, our ﬁndings es-
tablish that a single-point mutation ablating the ability of the
CCT domain to interact with RFXI motifs on its WNK activators
or ion co-transporters substrates is sufﬁcient to markedly reduce
phosphorylation and levels of NCC/NKCC2 resulting in a
∼20 mmHg reduction in BP. Strikingly, the impact of the CCT do-
main mutation is similar to that observed previously by ablating
SPAK kinase activity in knock-in mice (30) or by complete knock-
out of SPAK protein in mice (27–29). The SPAKL502A/L502A animals
still possess OSR1, which is activated normally byWNK isoforms
(Fig. 2D), emphasising that inhibiting SPAK without effecting
OSR1 is sufﬁcient to markedly lower BP. This is consistent with
previous analysis indicating that SPAK in mammals evolved as
a result of a gene duplication of OSR1, to undertake more
specialized roles such as control of NCC/NKCC2 in the kidney
and regulation of BP (1).
Intriguingly, in the SPAKL502A/L502A knock-in animals in add-
ition to a reduced phosphorylation of NCC/NKCC2, we observed
that the levels of NCC and NKCC2 protein were signiﬁcantly re-
duced (Fig. 3), under conditions which mRNA levels were un-
affected (Supplementary Material, Fig. S2). Similar results were
also observed when analysing catalytically inactive SPAK
knock-in mice (30). In converse, in mouse models in which the
WNK signalling pathway is activated by introducing knock-in
mutations that inhibit the ubiquitylation of and proteasomal
degradation of WNK4 (i.e. WNK4 [D561A] knock-in mice (31,43)
or KLHL3[R528H] knock-in mice (42)), NCC and NKCC2 protein le-
vels aremarkedly elevated. Taken together results provide strong
genetic evidence that phosphorylation of NCC/NKCC2 by SPAK in
addition to regulating co-transporter activity also promotes the
stability of these critical co-transporters. Furtherwork is required
to unravel themechanism, by which NCC and NKCC2 expression
is controlled by SPAK phosphorylation.
The plasma and urinary electrolyte pattern of the
SPAKL502A/L502A knock-in mice resembles Gitelman Syndrome.
In fact, it recapitulates closely the phenotype of our previous re-
portwith a kinase-dead SPAK knock-inmouse (30). The extensive
loss of NKCC2 and phospho-NKCC2 from the TAL tubules could
be expected to produce amore extensive or even Bartter-like Syn-
drome (44). The levels of NKCC2 were also reduced in the kinase-
dead SPAK knock-in mouse, but the reduction was modest in
comparison with almost complete loss of phosphorylated
NKCC2 from the SPAKL502A/L502A mouse kidney (Figs 3 and 4).
Nevertheless, the presence of both hypocalciuria and hypomag-
nesaemia in the SPAKL502A/L502A mice is in keeping with a pre-
dominant loss of NCC function, because the loss of NKCC2
function in themouse is associated with the opposite phenotype
of hypermagnesaemia and hypercalciuria (45). In fact, plasma
magnesium levels and urinary calcium excretion are clinical
measures used routinely to distinguish between Gitelman and
the related Bartter syndrome (46). Our ﬁnding that the total
level and phosphorylation of NKCC2 is reduced in the kidneys
of the SPAKL502A/L502A mouse is also notable because previous
SPAK knockout models reported hypophosphorylated NCC in
the DCT, but markedly hyperphosphorylated NKCC2 in the TAL
with increases in total NKCC2 levels (27) or without a change in
total NKCC2 levels (28,29). The authors suggested that this was
due to the removal of an inhibitory isoform of SPAK (SPAK2)
and showed that the hypophosphorylation of NCC was accom-
panied by physical reduction in numbers of DCT1 tubular seg-
ments. Similarly, other studies with mouse models of NCC
genetic ablation (47) and knockout of the DCT1-speciﬁc cal-
cium-binding protein, parvalbumin (48), have also shown atro-
phy of the DCT. SPAK has been reported to be directly involved
in the stabilisation of OSR1 at the apical membrane in the DCT
and SPAK knockout results in a signiﬁcant reduction of parvalbu-
min expression (29). However, unlike the knockout models used
in these studies, the SPAK scaffolding functions remain intact in
the point-mutant knock-in SPAKL502A/L502A and SPAKT243A/T243A
mice generated through heterozygous breeding was subjected to PCR to generate a product that encompasses the knock-in mutation region. The resultant PCR products
were ligated into the pCR-Topo 2.1 vector and transformed into E. coli, and clones were sequenced. Thewild-type and knock-in sequences are presented. (B) Expression of
SPAK in tissues (kidney, brain, heart and testis) fromwild-type and knock-in mice. The indicated tissue extracts (40 µg protein) fromwild-type and SPAK502A/502Amice
were subjected to immunoblot analysis with the speciﬁed antibodies. Immunoblots were run in parallel and exposed for the same amount of time to ensure that signal
intensities can be directly compared. Similar results were obtained in three separate experiments. (C and D) Activity of SPAK in wild-type and knock-in mouse tissues.
SPAK was immunoprecipitated from the kidney, testis and brain lysates from wild-type and SPAK502A/502A mice using the SPAK-mouse peptide antibody. The
immunoprecipitates were subjected to activity measurements using the CATCHtide peptide substrate (3). A fraction of the immunoprecipitates was also subjected to
immunoblot assay with the indicated antibodies.
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Figure 3. Reduced phosphorylation of SPAK, NCC, NKCC1, NKCC2 and expression of NCC and NKCC2 in both male and female SPAKL502A/L502A. (A) Expression of WNK1,
WNK4, SPAK, OSR1 and Parvalbumin and phosphorylation of SPAK in wild-type and knock-in male and female mouse kidney. Kidney extract derived from the indicated
mice was subjected to immunoblot analysis with the indicated antibodies. Each sample was derived from a separate littermate animal. Band intensities were quantiﬁed
using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney extracts derived
from different animals on each occasion with consistent results. (B) The right panel shows quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01;
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mice. Thismay explainwhywe observed no changes in the levels
or staining of parvalbumin (Figs 3A and 4). It is, therefore, pos-
sible to postulate that these remodelling phenomenamay largely
be due to loss of key components of regulatory pathways which
maintain normal tubular structure, rather than a simply loss of
NCC activity.
The altered shape of the arterial pressure waveform in our
SPAKL502A/L502A mice (Fig. 5B) is consistent with increased vascu-
lar compliance and reduced wave reﬂection in the periphery as
compared with the wild-type animals. This may be explained
in part by a diminished cardiac output arising from possible
reductions in cardiac contractility owing to loss of NKCC1
activity in the heart (49) (Fig. 2B) and the lower heart rates of
the SPAKL502A/L502Amice (Fig. 5A), because augmentation is nega-
tively correlated with heart rate in humans (50). It has also been
previously shown that intracranial administration of bumeta-
nide can be used to inhibit the over activity of NKCC1 in the hypo-
thalamic paraventricular nucleus of spontaneously hypertensive
rats. The inhibition of NKCC1 in these hypertensive animals acts
to reduce sympathetic vasomotor tone and lower their heart
rates (51). A similar phenomenon may be occurring in the
SPAKL502A/L502A mice owing to reductions in brain phospho-
NKCC1 (Fig. 2), thus providing a potential neurological explan-
ation for their lower heart rate and reduced vascular tone.
However, SPAK directly affects vascular smooth muscle con-
traction through WNK1 (52) and WNK3 (53) signalling and
NKCC1 (27), the activity of which is necessary for maintaining
vascular smoothmuscle tone (54), so it is likely that reduced aug-
mentation also reﬂects hypophosphorylation of NKCC1 in blood
vessels in a parallel fashion to our ﬁndings in the kidney and
other tissues (Figs 2 and 3). This is further supported by the short-
er τbourgeois found in SPAK
L502A/L502A mice, which implies reduced
vascular resistance consistent with a reduction in vascular con-
tractility. This suggests that targeting the CCT domain of SPAK
may have an additional effect on BP through a direct reduction
in vascular tone. It also suggests a reduced arterial stiffnesswith-
out a change in pulse pressure (Fig. 4), and both are importantly
independent risk factors for cardiovascular mortality (42).
There is increasing interest in targeting the WNK-SPAK/
OSR1-signalling pathway as a new therapeutic strategy to treat
hypertension (16,35). Our ﬁnding that ablation of the CCT do-
main function is sufﬁcient to reduce BP to the same extent as
a kinase ablating knock-in mutation (30) suggests that the CCT
domain of SPAK plays a similarly important role as the kinase
domain in controlling BP. Thus, inhibitors that prevent the
CCT domain-recognising RFXV motifs should be as effective as
compounds that target the protein kinase domain of SPAK in low-
ering BP. Structural analysis reveals that CCT domain recognises
RFXV/I motifs by adopting a unique fold not observed on other
proteins (40). This may indicate that CCT domain inhibitors
might be inherently more speciﬁc than ATP competitive kinase
inhibitors that would have the potential to target other protein
kinases and/or ATP binding enzymes. For the treatment of a
chronic largely asymptomatic condition such as hypertension,
it is particularly important that therapies are as speciﬁc as pos-
sible in order to reduce poorly tolerated off-target side effects.
Owing to the high degree of homology between the CCT do-
main of SPAK and OSR1, it may be impossible to develop drugs
that selectively inhibit SPAK. However, even a drug that partially
inhibited both SPAK and OSR1 isoforms might reduce phosphor-
ylation and expression of NCC and NKCC1/2 enough to lower BP
without signiﬁcant adverse effects. Thus far one CCT domain in-
hibitor termed STOCK 1S-50699 has been reported that has an
IC50 of ∼3 µ, that is capable of inhibitingWNK-SPAK phosphor-
ylating NKCC1 and NCC in mammalian cell lines (11,39). STOCK
1S-50699 is highly hydrophobic, displays poor solubility and can-
not be used in animal models, but the data obtained so far pro-
vide evidence that the development of CCT domain inhibitors
is feasible.
In conclusion, our results establish that the SPAKCCT domain
plays amajor role in regulating BP. Our data suggest that the SPAK
CCT domain regulates BP by promoting SPAK activation by WNK
isoforms that in turn enhance both activity and expression of the
renal sodium co-transporters NCC and NKCC2 with potential
concomitant effects on NKCC1 in the vasculature. The hypoten-
sive phenotype of the SPAKL502A/L502A mice validate the CCT do-
main as a promising new target for future anti-hypertensive
agents. The lack of an overt phenotype in these mice also indi-
cates that CCT domain inhibitors may be well tolerated.
Materials and Methods
Materials
Lumio Green, Colloidal Blue staining kit and precast SDS poly-
acrylamide BisTris gels were from Invitrogen. GL Biochem
synthesized all peptides to a purity of >95%; peptide sequences
were determined by mass spectrometry. Tissue-culture reagents
were from Life Technologies. P81 phosphocellulose paper was
from Whatman, and [γ-32P]-ATP was from PerkinElmer.
***P < 0.001. (C) Analysis of kidney NCC protein levels and phosphorylation inmale and femalewild-type and homozygous knock-inmice following NCC immunoblot and
immunoprecipitation. The upper panel shows that NCC from the indicated kidney extracts was subjected to immunoblot analysis with the total NCC antibody and a
phosphospeciﬁc antibodies recognizing NCC phosphorylated at Thr46, 50, 55, 60 and Ser91 (Thr60 is a key SPAK/OSR1 phosphorylation site in NCC is frequently
detected in Asian patients with Gitelman’s syndrome). The down panel shows that NCC was immunoprecipitated from the indicated kidney extracts and subjected to
immunoblot analysis with the total NCC antibody and a phosphospeciﬁc antibodies recognizing NCC phosphorylated at Thr46, 50, 55 and 60. Band intensities were
quantiﬁed using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney
extracts derived from different animals on each occasion with consistent results. (D) The right panel shows quantiﬁcation of the results of the blots (n = 6,
mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001. (E) Analysis of kidney NKCC2 protein levels and phosphorylation in male and female wild-type and homozygous knock-in
mice following NKCC2 immunoprecipitation. NKCC2 was immunoprecipitated from the indicated kidney extracts and subjected to immunoblot analysis with the total
NKCC2 antibody and a phosphospeciﬁc antibodies recognizing NKCC2 phosphorylated at Ser91, Thr100 and Ser130, a major SPAK phosphorylation site. Each sample is
derived from a separate littermate animal. Band intensities were quantiﬁed using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. The
study has been repeated over three times each with kidney extracts derived from different animals on each occasion with consistent results. (F) The right panel shows
quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001. (H) Analysis of kidney NKCC1 protein levels and phosphorylation in male and
femalewild-type and homozygous knock-inmice followingNKCC1 immunoblot and immunoprecipitation. The upper panel shows that NKCC1 from the indicated kidney
extracts was subjected to immunoblot analysis with the total NKCC1 antibody and a phosphospeciﬁc antibodies recognizing NKCC1 phosphorylated at Thr203, 207, 212
and 217. The down panel shows that NKCC1 was immunoprecipitated from the indicated kidney extracts and subjected to immunoblot analysis with the total NKCC1
antibody and a phosphospeciﬁc antibodies recognizing NKCC1 phosphorylated at Thr203, 207, 212 and 217. Band intensities were quantiﬁed using Li-Cor Odyssey,
and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney extracts derived from different
animals on each occasion with consistent results. (I) The right panel shows quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4. Immunolocalisation of NCC and NKCC2 in the renal tubules of SPAKL502A/L502A Mice. Representative pseudocoloured average intensity z projections of
immunoﬂuorescent-stained kidney sections (n = 4 per genotype) showing the distribution of total and phospho proteins in the TAL marked by total NKCC2 (tNKCC2),
early distal convoluted tubule (DCT1) marked by parvalbumin (PVALB) and whole distal convoluted tubule (DCT1/2) marked by total NCC (tNCC). Phospho-NCC T46
(pNCC) and phospho-NKCC2 S91 (pNKCC2) are virtually undetectable in the SPAKL502A/L502A mice. Scale bar = 100 µm.
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Plasmids
C-terminal human SPAK, full length, N-, C-terminalmouse SPAKs
were ampliﬁed employing SuperScript III (Invitrogen) from pla-
centa total RNA (Stratagene) using appropriate oligonucleotides.
The RT–PCR products were ligated into pCR2.1-TOPO vector and
sequenced. The sequence-veriﬁed SPAKs were sub-cloned into
bacterial (pGEX-6P-1) and mammalian (pCMV5) expression vec-
tors using BamHI and NotI. Required amino acid mutations were
introduced into the pCR2.1-TOPO clone using site-directed muta-
genesis by QuikChange method (Stratagene) but substituting the
Taq enzyme with KOD Hot Start DNA polymerase (Novagen). All
DNA plasmids used in this study are listed in Supplementary
Material, Table S1. Oligonucleotides were obtained from Invitro-
gen Life Sciences.DNAsequencingwasperformedbyTheSequen-
cing Service, College of Life Sciences, University of Dundee (www.
dnaseq.co.uk). All recombinant proteins, plasmids and antibodies
generated for the present study are available on request and
are described in additional detail on our website for reagents
(https://mrcppureagents.dundee.ac.uk/).
Expression and puriﬁcation of proteins in Escherichia coli
All pGEX-6P-1 constructs encoding expression of recombinant
with N-terminal Glutathione-S-Transferase (GST) tags were
transformed into BL21 E. coli cells, and 1-l cultures were grown
at 37°C in Luria Broth containing 100 µg/ml ampicillin until the
absorbance at 600 nm was 0.8. Isopropyl ß--thiogalactopyrano-
side (30 µ) was then added, and the cells were cultured for a
further 18 h at 26°C. Cells were isolated by centrifugation, re-
suspended in 40 ml of ice-cold lysis buffer and lysed in one
round of freeze/thawing, followed by sonication (Branson Digital
Soniﬁer; ten 15-s pulses with a setting of 45% amplitude) to frag-
ment DNA. Lysates were centrifuged at 4°C for 15 min at 26 00 g.
The GST-SPAK recombinant proteins were afﬁnity-puriﬁed on
0.5 ml glutathione–Sepharose and eluted in buffer A containing
0.27  sucrose and 20 m glutathione.
Fluorescence polarization
Fluorescence polarization measurements were performed at
25°C with puriﬁed SPAK proteins in 50 m Tris–HCl, pH 7.5,
150 m NaCl and 2 m DTT. The concentration of the SPAK pro-
teins was determined by measuring their absorbance at 280 nm
and calculated using the molar absorption coefﬁcient deter-
mined by the ProtParam Online tool (55). All peptides [SEEGKP
QLVGRFQVTSSK (EP4543) and SEEGKPQLVGAFQVTSSK (EP4544)]
contained an N-terminal linker required for conjugating to the
Lumio Green ﬂuorophore (CCPGCCGGGG) and were initially
resuspended in 50 m ammonium bicarbonate, pH 8. Peptide
labelling was achieved by incubating 10 n of each peptide in a
0.5 ml reaction mixture of 20 μ Lumio Green in 25 m Tris–
HCl, pH 7.5, 200 m NaCl and 5 m 2-mercaptoethanol. Reac-
tions were left to proceed in the dark for 2 h. The peptides were
dialysed for 4 h into 25 m Tris–HCl, pH 7.5, 200 m NaCl and
5 m 2-mercaptoethanol using a Micro DispoDIALYZER with a
100-Da molecular-mass cut-off (Harvard Apparatus) and then
for another 12 h with changed buffer. For ﬂuorescence polariza-
tion, mixtures were set up containing the indicated concentra-
tion of protein, 10 n Lumio-Green-labelled peptide in a ﬁnal
volume of 30 μl. All individual bindings were performed in dupli-
catewith at least 12 data points per curve. Fluorescence polariza-
tion measures were made using a BMG PheraStar plate reader,
with an excitation wavelength of 485 nm and an emission
wavelength of 538 nm, and measurements were corrected to
the ﬂuorescent probe alone. Data analysis and graphing were
then performed in GraphPad Prism6; a one-site-speciﬁc binding
Figure 5. Blood pressure and pressure waveforms of SPAKL502A/L502A mice. (A) Intravascular carotid measurements of systemic systolic blood pressure (SBP) and diastolic
blood pressure (DBP), and heart rate (HR) determined by ECG R-R wave interval inmice under general anaesthesia. (B) Pulsewaveform analysis reveals no change in pulse
pressure (PP) (SBP–DBP) but does show decreased augmentation pressure (AP) (SBP–anacrotic notch [AN] pressure), dicrotic notch (DN) pressure andMAP (1/3 × SBP + 2/3 ×
DBP) in the SPAKL502A/L502Aversuswild type. This hypotensive phenotype is in part owing to changes in vascular contractility in SPAKL502A/L502Amice as evidenced by their
lower augmentation index (AIx) [AP/PP], a marker of arterial stiffness, and is further supported by a decrease in their diastolic pressure decay time constant (τbourgeois)
(1/slope of diastolic pressure decay; measured 30 ms after DN and 20 ms before end DBP), a surrogate marker of decreased vascular resistance. Bars are mean ± SEM,
n = 8–9. Signiﬁcant differences from the SPAK wild type are shown by: *P < 0.02, **P < 0.001.
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model was assumed (Y = Bmax *X/[Kd +X]) and the ﬁtted dissoci-
ation constant computed. All experimental bindings were re-
peated at least twice and comparable results to those shown in
the present study were obtained.
Cell culture and transfections
HEK293 (human embryonic kidney 293) cells were cultured on
10-cm-diameter dishes in DMEM supplemented with 10% (v/v)
foetal bovine serum, 2 m -glutamine, 100 U/ml penicillin and
0.1 mg/ml streptomycin. For transfection experiments, each
dish of adherent HEK293 cells was transfected with 20 μl of
1 mg/ml polyethylenimine (Polysciences) and 5–10 μg of plasmid
DNA as described previously (56). Thirty-six hours post-transfec-
tion, cells were lysed in 0.3 ml of ice-cold lysis buffer/dish, lysates
were clariﬁed by centrifugation at 4°C for 15 min at 26 000g and
the supernatants were frozen in aliquots in liquid nitrogen and
stored at −20°C. Protein concentrations were determined using
the Bradford method.
Buffers
Lysis buffer was 50 m Tris–HCl, pH 7.5, 1 m EGTA, 1 m EDTA,
50 m sodium ﬂuoride, 5 m sodium pyrophosphate, 1 m so-
dium orthovanadate, 1% (w/v) NP-40 or 1% (w/v) Triton X-100,
0.27  sucrose, 0.1% (v/v) 2-mercaptoethanol and protease inhi-
bitors (one tablet per 50 ml). Buffer A was 50 m Tris–HCl, pH
7.5, 0.1 m EGTA and 0.1% (v/v) 2-mercaptoethanol. TBS-Tween
buffer (TTBS) was Tris–HCl, pH 7.5, 0.15  NaCl and 0.2% (v/v)
Tween-20. SDS sample buffer was 1× NuPAGE LDS sample buffer
(Invitrogen), containing 1% (v/v) 2-mercaptoethanol.
Antibodies
The following antibodies were raised in sheep and afﬁnity puri-
ﬁed on the appropriate antigen by the Division of Signal Trans-
duction Therapy Unit at the University of Dundee: WNK1-total
antibody (residues 2360–2382 of human WNK1, S62B), WNK4-
total antibody (residues 1221–1243 of human WNK4, S064B),
Figure 6. Plasma and urine electrolyte levels of SPAKL502A/L502A mice. (A) Plasma electrolytes (n = 12–16 per genotype per electrolyte) and (B) creatinine normalised urinary
electrolytes (n = 16–18 per genotype per electrolyte). (C) Urinary Na+ excretion expressed as mmol Na+/mmol creatinine at various time points after switching from a
3% w/w to a 0.03% w/w salt diet. Inset (C) shows the areas under the two curves (AUC) (n = 16 per genotype). Bars are mean ± SEM. Signiﬁcant differences from the
SPAK wild type are shown by: *P < 0.02, **P < 0.01, ***P < 0.005.
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WNK4 N-terminal antibody (residues 1–14 of mouse WNK4,
S726D), SPAK-mouse antibody (2–76 of mouse SPAK, S668D),
OSR1 mouse antibody (389–408 of mouse OSR1, SAHLPQPAGQ
MPTQPAQVSL, S149C), SPAK/OSR1 (T-loop) phospho-Thr233/
Thr185 antibody (226–238 of human SPAK or residues 178–190
of human OSR1, TRNKVRKpTFVGTP, S204C), SPAK/OSR1
(S-motif ) phospho-Ser373/Ser325 antibody (367–379 of human
SPAK, RRVPGSpSGHLHKT, which is highly similar to residues
319–331 of human OSR1 in which the sequence is RRVPG
SpSGRLHKT, S670B), SPAK phospho-Thr233 antibody (226–238
of human SPAK, TRNKVRKpTFVGTP, S668B), NKCC1 phospho-
Thr203 + Thr207 + Thr212 (residues 198–217 of human NKCC1,
HYYYDpTHTNpTYYLRpTFGHNT, S763B), NKCC1 phospho-Thr
212 + Thr 217 (residues 208–223 of human NKCC1, YYLRpT
FGHNpTMDAVPR, S063D), NKCC1-total antibody (residues 1–260
of shark NKCC1, S841B), NCC phospho-Thr46 + Thr50 + Thr55
antibody (residues 41–60 of human NCC phosphorylated at
Thr46 + Thr50 + Thr55, HPSHLpTHSSpTFCMRpTFGYNT, S908B),
NCC phospho-Thr46 antibody (residues 40–54 of human NCC
phosphorylated at Thr46, SHPSHLpTHSSTFCMRRR, S241C), NCC
phospho-Thr60 antibody (residues 54–66 of human NCC phos-
phorylated at Thr60, RTFGYNpTIDVVPT, S995B), NCC phospho-
Ser91 antibody (residues 85–97 of human NCC phosphorylated
at Ser91, CTLADLHpSFLKQEGRR, S996B), NCC-total antibody (resi-
dues 906–925 ofhumanNCC,CHTKRFEDMIAPFRLNDGFKD, S965B),
NKCC2 phospho-Thr100 (residues 94–106 of human NKCC2,
NTYYLQpTFGHNTM, S431C), NKCC2 phospho-Ser130 (residues
123–137 of human NKCC2, GPKVNRPpSLLEIHEQ, S888C), NKCC2
phospho-Ser91 (residues 86–97 of human NKCC2, RRFHAYD
pSHTNTYYRR, S451C), NKCC2-total antibody (residues 1–174 of
human NKCC2, S838B), GST-total antibody (raised against the
glutathione S-transferase protein, S902A) and ERK1 total anti-
body (full-length human ERK1 protein, S221B). The anti-GAPDH
antibody (ab8245), anti-NCC-total [SLC12A3] (AB95302) and the
anti-parvalbumin antibody (ab11427) were purchased from
Abcam. Anti-PVALB (Parvalbumin PV25) from Swant. Anti-NKCC2-
total (LS-C313275) from LifeSpan BioSciences. The anti-ERK1/2
antibody (9102) was purchased from Cell Signalling Technology.
The anti-FLAG antibody (F1804) was purchased from Sigma–
Aldrich. Secondary antibodies coupled to horseradish peroxidase
used for immunoblotting were obtained from Pierce. Fluoro-
chrome-conjugated secondary antibodies for immunoﬂuores-
cent confocal microscopy were obtained from Life Technologies
and Abcam. Pre-immune IgG used in control immunopreci-
pitation experiments were afﬁnity puriﬁed from pre-immune
serum using protein G-Sepharose.
Immunoprecipitation and assay of SPAK
One milligram of clariﬁed cell lysate was incubated with 5 µg of
the SPAK/OSR1 (total) antibody conjugated to 5 µl of protein
G-Sepharose and incubated for 2 h at 4°C with gentle agitation.
The immunoprecipitates were washed twice with 1 ml of lysis
buffer containing 0.5  NaCl and twice with 1 ml of buffer
A. The SPAK/OSR1 immunoprecipitates were assayed with the
CATCHtide peptide substrate (RRHYYYDTHTNTYYLRTFGHN
TRR) that encompasses the SPAK/OSR1 phosphorylation sites
on NKCC1 (3). Assays were set up in a total volume of 50 µl in buf-
fer A containing 10 m MgCl2, 0.1 m [γ32P]ATP and 300 µ
CATCHtide (37). After incubation for 30 min at 30°C, the reaction
mixture was applied onto P81 phosphocellulose paper, the
papers were washed in phosphoric acid and incorporation of
32P-radioactivity in CATCHtide was quantiﬁed by Cerenkov
counting.
Immunoblotting and total-antibody
immunoprecipitation
Cell lysates (15 µg) in SDS sample buffer were subjected to elec-
trophoresis on polyacrylamide gels and transferred to nitrocellu-
lose membranes. The membranes were incubated for 30 min
with TBS-T containing 5% (w/v) skim milk. The membranes
were then immunoblotted in 5% (w/v) skim milk in TBS-T with
the indicated primary antibodies overnight at 4°C. Sheep anti-
bodies were used at a concentration of 1–2 µg/ml. The incubation
with phospho-speciﬁc sheep antibodies was performed with the
addition of 10 µg/ml of the dephospho-peptide antigen used to
raise the antibody. The blots were then washed six times with
TBS-T and incubated for 1 h at room temperaturewith secondary
HRP-conjugated antibodies diluted 5000-fold in 5% (w/v) skim
milk in TBS-T. After repeating the washing steps, the signal was
detected with enhanced chemiluminescence reagent. Immuno-
blots were developed using a ﬁlm automatic processor (SRX-
101; Konica Minolta Medical), and ﬁlms were scanned with a
600-dpi resolution on a scanner (PowerLook 1000; UMAX). Figures
were generated using Photoshop/Illustrator (Adobe). For total-
antibody immunoprecipitationNCC,NKCC1 andNKCC2were im-
munoprecipitated from indicated kidney extracts. A 2 mg aliquot
of the indicated clariﬁed kidneyextractwere incubatedwith 15 μg
of the indicated total NCC, NKCC1 and NKCC2 antibodies conju-
gated to 15 μl of protein-G–Sepharose. Incubation was for 2 h at
4°C with gentle agitation, and the immunoprecipitates were
washed three times with 1 ml of lysis buffer containing 0.15 
NaCl and twice with 1 ml of buffer A. Bound proteins were eluted
with 1× lithium dodecyl sulphate (LDS) sample buffer.
Generation and genotyping of SPAK knock-in mice
The knock-in mice were generated by TaconicArtemis (http://
www.taconic.com/wmspage.cfm?parm1=1453) as described in
Figure 2A. The knock-in mice were generated and maintained
on an inbred C57BL/6J background. Genotyping was performed
by PCR using genomic DNA isolated from tails or embryonic
membranes. For the SPAK mice, Primer 1 (5′ TCT GTA AGC TCA
TTT ATG TAG TCA CC 3′) and Primer 2 (P2: 5′ CAA GTG AGT
GAG TGA ATA CAG CC 3′) were used to detect the wild-type and
knock-in alleles as described in Figure 2A. The PCR programme
consisted of 2 min at 95°C, 30 s at 95°C, 1 min at 60°C and 1 min
at 72°C: 35 cycles; 10 min at 72°C. DNA sequencingwas performed
by The Sequencing Service, College of Life Sciences, University of
Dundee, UK (www.dnaseq.co.uk).
Mice were maintained under speciﬁc pathogen-free condi-
tions, and all procedures were carried out in accordance with
the regulations set by the Universities of Cambridge and Dundee,
and the United Kingdom Home Ofﬁce.
Sample preparation and immunostaining for imaging
Harvested mouse tissues were immersion ﬁxed in fresh 4% (w/v)
formaldehyde-PBS pH 6.9 for 16 h at 37°C andwashed three times
in PBS and stored at 4°C until parafﬁn embedded. Five-micro-
metre sections were deparafﬁnised in Histoclear (National Diag-
nostics) and rehydrated in graded methanol steps. An antigen
retrieval step was performed with R-Universal buffer in the
2100 antigen retriever for a single heat-pressure cycle (Aptum
Biologics). Sections were permeabilised with 0.05% (v/v) Triton
X-100–PBS for 20 min and blocked for 1 h at 37°C with 2% (v/v)
donkey serum in 0.05% (v/v) Triton X-100–PBS. Primary anti-
bodies were incubated overnight for 16 h at 4°C at the following
concentrations diluted in 1% (v/v) donkey serum in 0.05% (v/v)
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Triton X-100–PBS: 2 μg/ml for pNCC T46, tNCC, pNKCC2 S91,
tNKCC2 and 4 μg/ml for WNK4 N-terminal and 1:2000 for
PVALB. Phospho-speciﬁc antibodies included the addition of
10 μg/ml of the non-phospho peptide used to raise the antibody
per 2 μg/ml of antibody used. Negative controls omitted the pri-
mary antibody and were processed in parallel (Supplementary
Material, Fig. S3). Slides were then washed for 20 min in 0.05%
(v/v) Triton X-100–PBS and incubated in secondary antibody for
1 h at 37°C. Pre-absorbed donkey IgG-conjugated Alexa Fluor
488, 633 and 647 secondary antibodies (Life Technologies/
Abcam) were used at 1:200 diluted in 1% (v/v) donkey serum in
0.05% (v/v) Triton X-100–PBS for immunoﬂuorescent labelling.
Slides were washed as mentioned earlier, counterstained using
Sytox orange nucleic acid stain (S11368—Life Technologies) and
mounted using Prolong gold antifade (P36930—Life Technolo-
gies) and shielded from light.
Image acquisition and processing
Immunoﬂuorescent images were acquired on the Leica TCS SP2
laser-scanning confocal with 488-, 543-, 633-nm laser lines
mounted on an upright Leica DM RXA ﬂuorescent microscope
using an HC PL FLUOTAR 20X/0.5NA objective. Acquisition para-
meterswere as follows: 12-bit, 1024 × 1024 pixels, 2× digital zoom,
800 Hz scan speed, 4-line Kalman ﬁltering, sequential (by line)
channel imaging and 10 slice z-stack of 5 µm.
In FIJI image analysis software, ﬂuorescent z-stacks under-
went background subtraction (1000px radius rolling ball, no
smoothing) and average intensity z-projection. Brightness and
contrast were adjusted by linear histogram stretching to enhance
visibility. Any images to be comparedwith one another were pro-
cessed evenly across thewhole image in parallel, the exception to
this were nuclei images where brightness and contrast were per-
formed on each image independently to ensure the best visibility.
In vivo pulse waveform analysis and BP measurements
Animals were anaesthetized with isoﬂurane on 100% O2 (induc-
tion: 3%,maintenance: 1.75%) and placed on a self-regulating rec-
tal probe-coupled heat mat (TC-1000; CWE) to maintain a body
temperature of 37°C. Heart rate was measured by the R-R wave
interval from ECG Lead II using an animal bio amp (FE136; AD In-
struments) with needle electrodes inserted into fore and hind
limbs (MLA1213; AD Instruments). The right carotid artery was
catheterized with a 1F Mikro-Tip pressure transducer (SPR-1000;
Millar) connected to a bridge amp (FE221; AD Instruments) and
powerlab system (PL3504/P; AD Instruments). When the animals
had stabilized, measurements were taken at 2000 samples/s
using lab chart version 7/8 pro (AD Instruments) to record ECG
and BP pulse waveforms.
Data processing and analysis was performed in Lab chart 8
pro. Using the BP add-on, systolic, diastolic and dicrotic notch
BPs were automatically detected per beat (beats with respira-
tory-induced artefact were gated out of the analysis using the
beats classiﬁer). Mean arterial pressure (MAP) was calculated as
(1/3 systolic pressure + 2/3 diastolic pressure) and pulse pressure
as (systolic pressure− diastolic pressure). Amacrowas scripted to
detect the anacrotic notch, by using the third zero value crossing
the fourth derivative of the pressure (57). The augmentation pres-
sure was calculated as (systolic pressure − anacrotic notch pres-
sure) and augmentation index as (augmentation pressure/pulse
pressure). A macro was scripted to measure the slope of the dia-
stolic pressure decay, 30 ms after the dicrotic notch and 20 ms be-
fore the end diastolic pressure (to avoid perturbations caused by
aortic valve opening/closing). The reciprocal of this slope (ignor-
ing the sign) was calculated from the 20% trimmed mean values
to determine the time decay constant of the diastolic pressure
decay (τbourgeois), which correlates with vascular resistance (41).
Data collection and analysis was carried out in a blinded fashion
throughout.
Plasma and urine electrolyte measurements
Animal were placed on a 3% w/w Na diet for 14 days with urine
andplasma samples collected on betweenDays 7 and 10 for base-
line. On Day 14, mice were switched onto a 0.03% w/w Na diet
with urine samples collected at 0, 3, 6, 12, 24 h after Na-diet
switch. Spot urine was collected from awake mice following
spontaneous micturition on handling over a sheet of Saran®
wrap or Paraﬁlm®. Sampleswere then divided and one sample re-
ceived acidiﬁcation with HNO3 to a ﬁnal concentration of 1% v/v
to prevent precipitation of electrolytes, before bothwere stored at
−80°C. Blood was collected by saphenous venepuncture in awake
restrained animals, and plasma was separated by using Microv-
ette® CB 300 LH (Sarstedt) centrifuged at 2000g for 5 min before
storage at −80°C.
Plasma and urine (non-acidiﬁed) creatinine levels were as-
sayed in the core Core Biochemical Assay Laboratory, Adden-
brooke’s Hospital, Cambridge, UK. Plasma and urine (acidiﬁed)
sampleswere diluted 1:1000 using ultra-pure polishedwater con-
taining 1% v/v HNO3. Cations were then measured using an
inductively coupled plasma—optical emission spectrometry
(Perkin Elmer ICP-OES Analyser) with known standards and
pre-set elemental spectra. Data collection and analysis was car-
ried out in a blinded fashion throughout.
Statistical analysis
Data are presented asmean ± SEM, with n representing the num-
ber of analysed mice. Mean values were compared by the
Student’s t-test for paired or unpaired observationswhere appro-
priate, using SigmaStat Program (Jandel Scientiﬁc, Chicago, IL,
USA) or GraphPad Prism5, or by ANOVA with post hoc testing
using version 15 of SPSS software. A P < 0.05 was considered stat-
istically signiﬁcant.
Supplementary Material
Supplementary Material is available at HMG online.
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